Close
Close
Research News

QIAGEN to Distribute altona Diagnostic's RealStar® Ebolavirus RT-PCR Kit 1.0, Recently Authorized by the FDA for Emergency Use

2.0
2.0 from 9 votes
Friday, December 05, 2014

Learn more about:

Access Programs

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announced it will offer global distribution of the altona Diagnostics RealStar® Ebolavirus RT-PCR Kit 1.0 after the U.S. Food and Drug Administration amended, on November 26, 2014 to permit authorized distribution and use in US and certain non-US laboratories, an Emergency Use Authorization (EUA) originally issued on November 10, 2014, for this kit. The diagnostic kit, developed and manufactured by altona Diagnostics GmbH, is a reverse transcription polymerase chain reaction (RT-PCR) test intended for the qualitative detection of RNA from all known strains of Ebolaviruses, including the Zaire strain driving the current Ebola epidemic in West Africa. QIAGEN has agreed to distribute the RealStar® Ebolavirus RT-PCR Kit 1.0 in addition to altona's already CE-IVD marked test, the RealStar® Filovirus RT-PCR Kit, which is for both Ebola and Marburg viruses and does not fall under the EUA.

"QIAGEN is taking an active role in the world's fight against Ebola, building on our capabilities as a leading provider of testing solutions demonstrated in previous outbreaks. We are making Ebola diagnostic workflows accessible to public health authorities, scientists and healthcare providers through our commercial networks around the world, including in Africa," said Peer M. Schatz, Chief Executive Officer of QIAGEN. "We are now also providing the RealStar® Ebolavirus kit for altona Diagnostics to help stop this deadly epidemic."

The RealStar® Ebolavirus kit is authorized for emergency use on specified instruments in plasma from individuals with signs and symptoms of Ebolavirus infection in conjunction with clinical and epidemiological risk factors. As authorized by the FDA under EUA, the test has not been FDA cleared or approved. It has been authorized by the FDA under an Emergency Use Authorization for use by CLIA High Complexity Laboratories and similarly qualified non-U.S. laboratories and only for the detection - not differentiation - of RNA from Ebolaviruses (such as Zaire ebolavirus, (including the Zaire ebolavirus strain detected in the West Africa outbreak 2014], Sudan ebolavirus, Tai Forest ebolavirus, Bundibugyo ebolavirus, and Reston ebolavirus) and not for any other viruses or pathogens. Furthermore, this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection of Ebola Zaire virus under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

QIAGEN's agreement with altona Diagnostics to distribute the FDA-authorized RealStar® Ebolavirus RT-PCR Kit 1.0 expands an existing collaboration between the two companies which was signed in the third quarter of 2014. Under the earlier agreement, QIAGEN is also distributing the RealStar® Filovirus RT-PCR Kit, which does not fall under the EUA, outside the United States. This highly sensitive test for Filoviruses (Ebola and Marburg) that is CE-IVD marked for use on QIAGEN instruments and with QIAGEN sample technologies outside the United States is also compatible with other widely used detection platforms present in many laboratories, helping to avoid the need for new equipment and additional trainings.

Other QIAGEN molecular testing technologies not covered by the EUA include components such as the EZ1 Virus Mini Kit v2.0, RNeasy and QIAamp Viral RNA Mini extraction kits as well as flexible automation platforms such as the QIAsymphony family, QIAcube and EZ1 Advanced instruments, which are being used by many laboratories around the world for Ebola research and diagnosis. Finally, QIAGEN's bioinformatics tools such as the CLC Genomics Workbench and Ingenuity Pathway Analysis have contributed to generating valuable insights into research on genetic factors driving individual response to Ebola infections.

About QIAGEN 

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of September 30, 2014, QIAGEN employed approximately 4,200 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

About altona Diagnostics GmbH 

altona Diagnostics, founded in 2007 in Hamburg, Germany, is focused on the development, approval, manufacturing, and marketing of molecular diagnostic test systems for the detection and quantification of pathogens. Altona is a fully integrated diagnostic company. The founders and staff of altona Diagnostics have a broad experience in molecular diagnostics and corresponding technologies. Among other activities, they were among the first to make reliable CE-IVD marked molecular diagnostic kit systems commercially available during outbreak situations for SARS, avian Flu, swine Flu and EHEC. altona Diagnostics is ISO 13485 certified.

Contact:

Media

Dr. Thomas Theuringer, Director Public Relations

Tel: +49-2103-29-11826 / +1-240-686-7425

pr@qiagen.com

http://www.twitter.com/qiagen

pr.qiagen.com

or

Investor

John Gilardi, Vice President Corporate Communications and Investor Relations

Tel: +49-2103-29-11711 / +1-240-686-2222

ir@qiagen.com

ir.qiagen.com

Source: QIAGEN
2.0
2.0 from 9 votes
Free Newsletter